Evidence map›Paper›PMID 32671101›Full record

ReviewFrontiers in cardiovascular medicine2020

Stereotactic Radiotherapy for the Management of Refractory Ventricular Tachycardia: Promise and Future Directions.

Raphael Jumeau, Mahmut Ozsahin, Juerg Schwitter, Olgun Elicin, Tobias Reichlin, Laurent Roten, Nicolaus Andratschke, Michael Mayinger, Ardan M Saguner, Jan Steffel and 9 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cardiovascular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Patient vulnerability in stereotactic arrhythmia radioablation (STAR): a preliminary ethical appraisal from the STOPSTORM.eu consortium.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Review
  12. Article
  13. Stereotactic radioablation for ventricular tachycardia.Herzschrittmachertherapie & Elektrophysiologie · 2022
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Raphael JumeauDepartment of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Mahmut OzsahinDepartment of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Juerg SchwitterHeart and Vessel Department, Cardiac MR Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Olgun ElicinDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Tobias ReichlinDepartment of Cardiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Laurent RotenDepartment of Cardiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Nicolaus AndratschkeDepartment of Radiation Oncology, University Hospital Zurich, Zürich, Switzerland.
Michael MayingerDepartment of Radiation Oncology, University Hospital Zurich, Zürich, Switzerland.
Ardan M SagunerDepartment of Cardiology, University Heart Center Zurich, Zürich, Switzerland.
Jan SteffelDepartment of Cardiology, University Heart Center Zurich, Zürich, Switzerland.
Oliver BlanckDepartment of Radiation Oncology and Department of Internal Medicine III, Cardiology, Section for Electrophysiology, University Medical Center Schleswig-Holstein, Kiel, Germany.
Marie-Catherine VozeninRadio-Oncology Research Laboratory, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Raphael MoeckliInstitute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Michele ZeverinoInstitute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Véronique ValletInstitute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Claudia Herrera-SiklodyHeart and Vessel Department, Service of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Patrizio PascaleHeart and Vessel Department, Service of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Jean BourhisDepartment of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Etienne PruvotHeart and Vessel Department, Service of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
University of Lausanne · CHUniversity Hospital of Zurich · CHUniversity of Bern · CHZurich Heart House · CHUniversity Hospital of Bern · CHUniversity Hospital Schleswig-Holstein · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ventricular tachycardia (VT) caused by myocardial scaring bears a significant risk of mortality and morbidity. Antiarrhythmic drug therapy (AAD) and catheter ablation remain the cornerstone of VT management, but both treatments have limited efficacy and potential adverse effects. Stereotactic body radiotherapy (SBRT) is routinely used in oncology to treat non-invasively solid tumors with high precision and efficacy. Recently, this technology has been evaluated for the treatment of VT. This review presents the basic underlying principles, proof of concept, and main results of trials and case series that used SBRT for the treatment of VT refractory to AAD and catheter ablation.

Indexed as

ablationnoninvasiveradiotherapystereotactic radiotherapyventricular tachycardia

Identifiers

PMID32671101
PMCPMC7329991
OpenAlexW3037534910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.